The Persistence of Biologic Therapies for Psoriatic Arthritis: A Narrative Review

Simple item page
dc.catalogadorpva
dc.contributor.authorJasmen Espinoza, Magdalena Sofía
dc.contributor.authorGarcía, Dominga
dc.contributor.authorIbáñez, Sebastián
dc.contributor.authorDíaz Álvarez, Pamela Alejandra
dc.date.accessioned2024-12-02T17:00:07Z
dc.date.available2024-12-02T17:00:07Z
dc.date.issued2024
dc.description.abstractDrug persistence is a crucial measure of long-term efficacy, safety, and patient satisfaction. Lack of persistence can increase healthcare costs and morbidity and mortality rates. This review aimed to consolidate available data on drug persistence for various biological treatments used as the primary intervention for psoriatic arthritis and identify factors associated with nonpersistence. Reports indicate variable 1-year persistence rates for biologic therapies, ranging from 37% to 73%. Specifically, tumor necrosis factor inhibitors have shown fluctuating 1-year persistence rates ranging from 32% to 85%. IL-12/23 and IL-23 inhibitors demonstrate persistence rates of 25% to 89%, whereas data for IL-17 and JAK inhibitors are more limited, ranging from 51% to 77%. Factors such as female sex and a higher burden of comorbidities have been associated with an increased risk of nonpersistence, although evidence regarding other factors remains scarce. The significant variability in reported persistence rates may be attributed to differences in treatment gaps and methodologies across studies. Addressing and mitigating the factors leading to nonpersistence is essential for improving treatment outcomes in psoriatic arthritis.
dc.format.extent10 páginas
dc.fuente.origenORCID
dc.identifier.doi10.1097/RHU.0000000000002159
dc.identifier.issn1076-1608
dc.identifier.urihttps://doi.org/10.1097/RHU.0000000000002159
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/88706
dc.information.autorucEscuela de Medicina; Jasmen Espinoza, Magdalena Sofía; S/I; 1089197
dc.information.autorucEscuela de Medicina; Díaz Álvarez, Pamela Alejandra; 0000-0001-9630-5439; 209525
dc.language.isoen
dc.nota.accesocontenido parcial
dc.pagina.final10
dc.pagina.inicio1
dc.publisherWolters Kluwer Health, Inc.
dc.revistaJCR: Journal of Clinical Rheumatology
dc.rightsacceso restringido
dc.subjectMedication persistence
dc.subjectDrug survival
dc.subjectBiologic therapy
dc.subjectPsoriatic arthritis
dc.subject.ddc610
dc.subject.deweyMedicina y saludes_ES
dc.subject.ods03 Good health and well-being
dc.subject.odspa03 Salud y bienestar
dc.titleThe Persistence of Biologic Therapies for Psoriatic Arthritis: A Narrative Review
dc.typeartículo de revisión
sipa.codpersvinculados1089197
sipa.codpersvinculados209525
sipa.trazabilidadORCID;2024-12-02
Files
Collections
Artículos de revistas